Huntemann, Niklas http://orcid.org/0000-0003-0015-8484
Rolfes, Leoni
Pawlitzki, Marc
Ruck, Tobias
Pfeuffer, Steffen
Wiendl, Heinz
Meuth, Sven G.
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Accepted: 15 April 2021
First Online: 4 June 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: Niklas Huntemann: declares no conflicts of interest. Leoni Rolfes: declares no conflicts of interest. Marc Pawlitzki: declares no conflicts of interest. Tobias Ruck: received personal fees from Alexion, Biogen, Merck Serono, Sanofi-Genzyme, Roche, and Teva, grants from Alexion and Sanofi-Genzyme, and nonfinancial support from Merck Serono. Steffen Pfeuffer: received travel reimbursements from Sanofi Genzyme and Merck Serono, honoraria for lecturing from Sanofi Genzyme, Biogen, and Mylan Healthcare, and research support from Merck Serono, Diamed, and the German Multiple Sclerosis Society North Rhine-Westphalia. Heinz Wiendl: received grants from German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, Biogen, GlaxoSmithKline GmbH, Roche, and Sanofi-Genzyme; consulting fees from AbbVie, Actelion, Argenx, Biogen, EMD Serono, Idorsia, IGES, Immunic, Merck, Novartis, Roche, Sanofi-Aventis, the Swiss Multiple Sclerosis Society, and UCB; support for travel to meetings for other purposes from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Hertie Foundation, Merck Serono, Novartis, Roche, Genzyme, Teva, and WebMD Global; fees for participation in review activities such as data monitoring boards from Polpharma Biologics; payment for lectures from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Hertie Foundation, Merck Serono, Novartis, Roche, Genzyme, Teva, and WebMD Global; honorarium for expert testimony from the Drug Commission of the German Medical Association. Sven G. Meuth: received honoraria for lecturing and travel reimbursement for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: NH: study concept and design, acquisition of data, analysis and interpretation of data, writing of the manuscript. LR: study concept and design, acquisition of data, writing of the manuscript. MP: critical revision of manuscript for intellectual content. TR: critical revision of manuscript for intellectual content. SP: critical revision of manuscript for intellectual content. HW: critical revision of manuscript for intellectual content. SGM: study concept and design, critical revision of manuscript for intellectual content.